The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment.
Journal
Case reports in hematology
ISSN: 2090-6560
Titre abrégé: Case Rep Hematol
Pays: United States
ID NLM: 101576456
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
02
2021
revised:
31
03
2021
accepted:
16
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
epublish
Résumé
In the era of tyrosine kinase inhibitor (TKI) treatment, its effectiveness in treating chronic myelogenous leukemia (CML) has been improved, ensuring the same prognosis as that of healthy people of the same age. However, there are some patients with de novo blast crisis that undergoes acute conversion from the time of diagnosis and does not respond to TKI treatment, especially in the older patients. Here, we present a case of an older patient with de novo lymphoid crisis who was first treated with a combination of TKI and chemotherapy, but it was difficult to maintain a durable deep molecular response (DMR). After he achieved major molecular response (MMR) or less, it was possible to suppress IS% to DMR by performing a combined treatment with interferon-
Identifiants
pubmed: 34055427
doi: 10.1155/2021/5518727
pmc: PMC8112961
doi:
Types de publication
Case Reports
Langues
eng
Pagination
5518727Informations de copyright
Copyright © 2021 Kunio Hayashi et al.
Déclaration de conflit d'intérêts
Kunio Hayashi and Kazuhiro Ikegame report no conflicts of interest regarding the content of this paper. Naoto Takahashi declares that he has received lecture fees and scholarship donations and conducted joint research with Otsuka Pharmaceutical.
Références
Cancer Manag Res. 2020 May 06;12:3175-3189
pubmed: 32440215
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Cancer. 2017 Nov 15;123(22):4391-4402
pubmed: 28743165
Leukemia. 2013 Apr;27(4):803-12
pubmed: 23238589
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
Rinsho Ketsueki. 2019;60(1):33-38
pubmed: 30726822
Am J Hematol. 2016 Jan;91(1):59-66
pubmed: 26769227
Cancer. 2016 Dec 1;122(23):3650-3656
pubmed: 27479888
PLoS One. 2016 May 23;11(5):e0155959
pubmed: 27214026
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Front Oncol. 2019 Aug 06;9:665
pubmed: 31448223